Supreme Court Raises Bar for Induced Infringement in ‘Skinny Label’ Generic Case

In a unanimous decision with immediate consequences for Hatch‑Waxman litigation, the U.S. Supreme Court has significantly narrowed the scope of induced patent infringement under 35 U.S.C. Section 271(b). In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the court made clear that allegations of inducement must be grounded in affirmative conduct that actually encourages infringement—not inferences drawn from ambiguous statements or routine commercial activity.

The decision marks an important course correction from recent Federal Circuit case law and provides meaningful clarity—and protection—for generic manufacturers pursuing “skinny label” strategies.

The case arose from Hikma’s launch of a generic version of Amarin’s Vascepa following Department of Food and Drug Administration (FDA) approval via a Section viii carve-out. Hikma’s label excluded Amarin’s patented cardiovascular (“CV”) indication, but Amarin nevertheless sued, arguing that a combination of Hikma’s label, website and public statements indirectly encouraged physicians to prescribe the drug for that patented use. The Federal Circuit allowed the case to proceed, reasoning that it was plausible that healthcare providers could interpret Hikma’s communications as encouraging infringement.

The Supreme Court rejected that approach. Emphasizing longstanding precedent, the court explained that induced infringement requires not only knowledge of infringement and underlying direct infringement, but also “active steps” taken to bring about that result. Those steps must reflect affirmative, purposeful conduct directed toward encouraging infringement, not merely conduct that could be interpreted that way after the fact. In doing so, the court drew a sharp distinction between statements that are designed to promote infringement and those that merely leave open the possibility that third parties might act on their own initiative. The court stopped short of requiring that active inducement be “express” however, acknowledging that implicit encouragement can be sufficient to reach active inducement.

Applying that standard, the court found that Amarin’s allegations fell short. Much of Hikma’s conduct, the court explained, was readily explained by regulatory requirements or standard industry practice. For example, generic drug labels must mirror the brand label aside from carved-out indications, and describing a product as a “generic equivalent” is both accurate and commonplace. Treating such conduct as evidence of inducement would effectively penalize compliance with the law—an outcome the court refused to endorse.

The Supreme Court was similarly unpersuaded by Amarin’s reliance on what Hikma did not say. Allegations based on omissions—such as failing to emphasize that the product was not approved for the patented CV use—could not support inducement, because liability under § 271(b) requires affirmative acts, not silence or inaction. Allowing omissions alone to suffice, the court cautioned, would risk sweeping in ordinary commercial behavior and exposing companies to liability based on speculative chains of inference.

Finally, the court rejected the argument that Hikma’s broader communications, including patient materials, website descriptions and press releases, collectively supported a plausible claim. Even taken together, those statements were too indirect and attenuated to show that Hikma had taken deliberate steps to encourage infringing use. The court emphasized that the law requires more than a conceivable pathway from a statement to infringement; it requires a plausible inference of intentional encouragement, grounded in concrete, affirmative conduct.

The implications of the decision are significant for both sides of the pharmaceutical industry. For generic and biosimilar manufacturers, the ruling provides stronger assurance that carefully structured skinny label strategies that align tightly with the carved-out indication—combined with routine regulatory compliance—will not, without more, give rise to inducement liability. The decision should also enhance defendants’ ability to dispose of such claims at the pleading stage, reducing the cost and uncertainty of protracted litigation.

For brand‑name companies, however, the decision raises the bar for enforcement. Induced infringement claims premised on ambiguity, omission or the cumulative effect of routine statements are unlikely to succeed. Instead, future cases will likely turn on whether there is clear evidence of targeted promotional conduct or messaging specifically designed to drive use for patented indications.

In short, the Supreme Court has drawn a clearer and more demanding line: induced infringement requires intentional encouragement, not interpretive possibility. Companies on both sides should revisit their labeling, communications and litigation strategies in light of this decision, which reshapes the boundaries of risk in skinny label disputes.

THIS DOCUMENT IS INTENDED TO PROVIDE YOU WITH GENERAL INFORMATION REGARDING the U.S. Supreme Court’s ruling Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.. THE CONTENTS OF THIS DOCUMENT ARE NOT INTENDED TO PROVIDE SPECIFIC LEGAL ADVICE. IF YOU HAVE ANY QUESTIONS ABOUT THE CONTENTS OF THIS DOCUMENT OR IF YOU NEED LEGAL ADVICE AS TO AN ISSUE, PLEASE CONTACT THE ATTORNEYS LISTED OR YOUR REGULAR BROWNSTEIN HYATT FARBER SCHRECK, LLP ATTORNEY. THIS COMMUNICATION MAY BE CONSIDERED ADVERTISING IN SOME JURISDICTIONS.